About Dr. Leissring

The research career of Malcolm A. Leissring, Ph.D., began in 1988 at the University of California, Berkeley, where he was engaged in basic research investigating how opioid peptides affect different stages of memory formation.

Seeking to apply his experience in learning and memory to human disorders, he conducted his predoctoral work in the laboratory of Frank M. LaFerla, Ph.D., at the University of California, Irvine. In addition to gaining experience with the generation and characterization of transgenic mouse models, Dr. Leissring's work there focused on the effects that Alzheimer's disease-associated mutations in the presenilin proteins have on intracellular calcium signaling.

For his postdoctoral studies, Dr. Leissring joined the laboratory of Dennis J. Selkoe, M.D., where he used a transgenic approach to show that proteolytic degradation of the amyloid-beta (Aβ) protein potently regulates amyloidogenesis in vivo. He also gained experience in high-throughput compound screening and medicinal chemistry, which he hopes to apply to the development of novel treatments for Alzheimer's disease based on activation or disinhibition of proteases that degrade Aβ.